AI-assisted eye screening for diabetic retinopathy and age-related macular degeneration in outpatient clinics

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized controlled trial at National Taiwan University Hospital comparing AI-assisted fundus-photo screening using VeriSee plus immediate physician explanation versus standard physician-only fundus interpretation. Adults with diabetes (age 20+) and adults aged 50+ who meet AMD screening criteria are randomized to one of the two screening approaches. Primary outcomes include detection rates of diabetic retinopathy and AMD, subsequent ophthalmology referrals and outcomes, patient and physician satisfaction, and a parallel cost-effectiveness analysis. Data collection is planned from April 2025 through December 2027 across the main and Bei-Hu hospital branches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.
* VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.

Exclusion Criteria:

* The patient does not agree to participate in the trial or is unable to provide informed consent.

Where it's running

• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Finding protein biomarkers for AMD, diabetic retinopathy, and retinal detachment

  This project will test whether proteins found in blood and eye fluids can help diagnose or predict outcomes for adults with AMD, diabetic retinopathy, or retinal detachment.

  Recruiting Fondazione G.B. Bietti, IRCCS · Roma, Italy · NCT07500324

• VeriSee AI for screening macular degeneration and diabetic retinopathy

  This trial will test whether the VeriSee AI software can help doctors screen for age-related macular degeneration in adults 50+ and diabetic retinopathy in diabetic adults 20+.

  Recruiting National Taiwan University Hospital · Taipei, Taiwan · NCT06843499

• Automated AI system to detect diabetic retinopathy in adults with diabetes

  A AI-based software device is being tested to automatically detect diabetic retinopathy from retinal images in adults with diabetes.

  Recruiting Digital Diagnostics, Inc. · Jacksonville, Florida · NCT07844317

• N-acetylcysteine for diabetic retinopathy in adults with type 2 diabetes

  This study tests whether taking N-acetylcysteine for three months can help people with type 2 diabetes who have mild to moderate diabetic retinopathy.

  Recruiting at 2 sites Phase 4 Ain Shams University · Cairo and 1 other locations · NCT07634991

• Early imaging changes with faricimab versus biosimilar ranibizumab for diabetic retinal disease

  This trial will see if faricimab or a biosimilar ranibizumab causes different early OCT and OCTA imaging changes in adults with diabetic retinopathy or diabetic macular edema who need anti-VEGF injections.

  Recruiting Osijek University Hospital · Osijek · NCT07520045

• Enhanced vision and imaging tests to enable treatments for early and intermediate AMD

  We will see if a fundus-tracked dark adaptometry test can reliably detect and track vision changes in people with early or intermediate AMD and in healthy volunteers.

  Recruiting University Hospital, Bonn · Bonn · NCT07515521

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.